Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial - Concepedia

Concepedia

Publication | Open Access

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial

DOI Full Paper Access

39

Citations

19

References

2025

Year

Jordana E. Hoppe, Ajay S. Kasi, Jessica E. Pittman, Renée Jensen, L. Thia, Philip Robinson, Pornchai Tirakitsoontorn, Bonnie W. Ramsey, Marcus Mall, Jennifer L. Taylor‐Cousar,

The Lancet Respiratory Medicine

Abstract

Vertex Pharmaceuticals.

References

	Year	Citations

Page 1